Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA

Meghna Jani, William G Dixon, Lianne Kersley-Fleet, Ian N Bruce, Hector Chinoy, Anne Barton, Mark Lunt, Kath Watson, BSRBR-RA Control Centre Consortium, Deborah P Symmons, Kimme L Hyrich

INTRODUCTION

Tumour necrosis factor-α inhibitor (TNFi) for the treatment of rheumatoid arthritis (RA) has been associated with asymptomatic immunological alterations to autoimmune pathology with systemic manifestations. A single case of lupus-like event (LLE) was reported following two infusions of infliximab in the first TNFi randomised controlled trial. The number and spectrum of autoimmune diseases reported to be induced by TNFi agents have increased in parallel with their widespread use. The most commonly described events are LLEs and vasculitis-like events (VLEs).
Induction of antinuclear antibodies (ANAs) following TNFis is well recognised, with a small proportion of patients developing immune-mediated adverse events (AEs), including LLE and VLEs.6,7 Seroconversion to ANA positivity has been associated with secondary non-response to TNFi treatment,3 4 and to the development of antidrug antibodies or immunogenicity7 with monoclonal antibody TNFi drugs (infliximab/adalimumab). Immunogenicity has itself also been linked to a diverse range of VLEs with varying degrees of severity, from limited cutaneous involvement to life-threatening systemic manifestations.6,7

Most data on LLEs and VLEs are derived from spontaneous pharmacovigilance, case reports and retrospective studies.8,9 While published data suggest a drug-specific difference in ANA seroconversion,9 reports to date do not enable robust comparison between drugs in terms of actual clinical AEs. Furthermore, it is not known if factors, such as concomitant non-biological disease-modifying anti-rheumatic drugs (nbDMARDs), attenuate the risk of these events, although their use is associated with reduced immunogenicity in TNFi-treated patients.10

The primary aim of this study was to determine the incidence of LLE and VLE in patients with RA treated with TNFi, compared to biological-naive patients treated with nbDMARDs. Additional objectives were to: (1) evaluate drug-specific risk, (2) determine the risk of each outcome following exclusion of putative causes and (3) identify factors associated with each outcome.

PATIENTS AND METHODS

Participants

The British Society for Rheumatology Biologics Register—RA (BSRBR-RA) is a UK-based national, observational, prospective cohort study established in 2001, which aims to study the long-term safety of biological treatment. Patients starting treatment with TNFi (infliximab, etanercept, adalimumab and certolizumab) are enrolled for observational follow-up. As per the UK national guidelines, patients are eligible for TNFi if they have active disease (disease activity score of 28 joints (DAS28) ≥5.1), despite treatment with at least two nbDMARDs, one of which should be methotrexate.11 A comparison cohort of biological-naive patients with RA, with active disease (defined as a DAS28 score of ≥4.2), despite current treatment with nbDMARDs, was recruited in parallel between 2002 and 2009. Ethical approval for BSRBR-RA was granted in December 2000 by the North West Multicentre Research Ethics Committee (reference 00/8/53). Written consent was obtained from all participants recruited.

Baseline assessment

Baseline demographic and clinical information was collected via clinician questionnaires. Consultants were specifically asked if the patient had a history of systemic vasculitis and nailfold vasculitis prior to starting a biologic. Other comorbidities, such as systemic lupus erythematosus (SLE), were recorded via a free text box. Self-reported ethnicity was captured within the baseline patient questionnaire. Patients were requested to complete a Stanford Health Assessment Questionnaire (HAQ).12

Follow-up

Follow-up information, including medication changes and AEs, were captured via three routes: clinician-completed questionnaires (6-monthly for 3 years then annually), patient diaries (6-monthly for first 3 years only) and flagging by the Office for National Statistics who notify the register in the event of death or cancer. All reports of serious events are follow-up with the hospital to request further information. For LLE, this was via a disease-specific pro-forma; for VLE, this was via open correspondence.

Case definition and verification of AEs

We used all relevant MedDRA codes and free text searches within the AE reported fields (see online supplementary table S4) to identify potential cases. All possible reported events of either LLE or VLE were reviewed in detail using information provided to the register. The types of LLE events described in previous literature from France, USA and Spain have been heterogeneous ranging from dsDNA-positive patients with cutaneous lupus to fewer ‘full blown’ lupus meeting ACR classification criteria.2 8 15 It has been argued that LLE associated with TNFi therapy is a distinct syndrome compared to SLE.14 Since classification criteria for drug-induced lupus does not currently exist, the Dubois’ guidelines for drug-induced lupus were used15 to provide a more sensitive definition. The full guidelines are outlined in online supplementary table S1. Briefly, this includes continuous treatment with a lupus-inducing drug for ≥1 month, common or multisystem presenting symptoms consistent with lupus, laboratory profile consistent with lupus and improvement of symptoms following drug cessation. Patients were classified as having an LLE if clinically identified as such and ≥2 criteria were met. Following verification (performed by MJ), LLE cases were additionally classified according to standard SLE classification criteria (1997 ACR16 and 2012 SLICC criteria17) for descriptive purposes only. A single set of classification criteria could not be applied due to the heterogeneous characteristics of vasculitis events, ranging from cutaneous to multisystem manifestations. Therefore, such reports were flagged as such by the reporting physician; verification was performed clinically following additional requests for clinical information where necessary.

Statistical analysis

Patients with a physician diagnosis of RA, who had at least one clinician-completed follow-up form by 31 May 2015, were included. The primary outcome was the first
verified LLE or first verified VLE per participant following the start of TNFi drug (or registration for the nbDMARD cohort). For the LLE analysis, patients with known SLE overlap recorded at baseline were excluded. Patients were excluded from the analysis if they had known systemic vasculitis at baseline. Events were attributed to TNFi if they occurred when the patient was receiving TNFi or within 90 days of the first missed dose. Follow-up time was censored at event of interest, death, drug stop date (plus 90 days) or last physician follow-up, whichever came first. Only time on a first TNFi was included to best attribute any drug-specific risk. In the nbDMARD cohort, follow-up time was censored if the patient switched to a biological drug.

Crude incidence rates were presented as events per 10 000 patient-years (pYrs). Cox proportional-hazard models were used to compare event rates between TNFi and nbDMARD cohorts. Cumulative hazards were compared between the different drugs using Nelson-Aalen plots. A flexible parametric spline model was used to model time-varying incidence rates in the TNFi cohort. Adjustment for differences between cohorts was made using propensity scores using inverse probability of treatment weights (IPTW; see online supplementary material). Variables were identified a priori and included age, gender, disease duration, HAQ score, baseline DAS28; rheumatoid factor status, recruitment year, baseline nbDMARD use, baseline oral steroid use and ethnicity (the latter variable for the LLE analysis only). Comorbidity was included as a composite variable generated from the presence of: ischaemic heart disease (myocardial infarction and/or angina); stroke, hypertension, chronic lung disease (asthma, bronchitis or emphysema), renal disease, liver disease, diabetes mellitus or depression as described previously.18 Ethnicity was stratified as white and non-white for analyses (table 1). Missing data were replaced using multiple imputation to avoid the bias induced by a complete case analysis (see online supplementary table S2).

Two sensitivity analyses were performed. For the LLE analysis, patients on drugs known to be associated with drug-induced lupus at baseline (see online supplementary table S3) and the use of sulfasalazine, leflunomide, minocycline and penicillamine were excluded.15 19 20 For the VLE analysis, patients who had a probable secondary vasculitis aetiology (eg, infection at the time of event), known baseline nailfold vasculitis, on other medications associated with VLEs at baseline (see online supplementary table S3) or use of minocycline and penicillamine during the study period were excluded.21 All analysis was performed using Stata V.13.0 (StataCorp, College Station, Texas, USA).

RESULTS
Baseline characteristics
A total of 3673 nbDMARD and 12 937 TNFi-treated patients were included (see online supplementary figure S1). The TNFi cohort was older, had proportionally more women with higher disease severity (table 1). Differences between patients treated with infliximab, etanercept and adalimumab were less marked while patients treated with certolizumab (registered after 2010) had shorter disease duration and less severe disease at initiation.

Event rates and hazard estimates
There were 59 LLEs (54 TNFi and 5 nbDMARD). The incidence of LLE was 10/10 000 pYrs (95% CI 8 to 13) in the TNFi cohort compared to 2/10 000 pYrs (95% CI 1 to 6) in the nbDMARD cohort. After full adjustment, the risk of LLE in TNFi-treated patients compared to nbDMARDs was no longer significant (adjHR 1.86; 95% CI 0.52 to 6.58) (table 2). The risk appeared highest for infliximab (figure 1). Female gender, non-white ethnicity, baseline DAS28 score, baseline HAQ score and minocycline use were associated with increased risk of LLE, while baseline and concomitant sulfasalazine use were associated with lower rates (table 3). Following exclusion of patients on drugs known to be associated with drug-induced lupus, the adjHR was 2.33 (95% CI 0.56 to 9.71) (see online supplementary table S3).

There were 95 cases of VLEs (81 TNFi and 14 nbDMARD) giving an incidence rate for VLE in the TNFi cohort of 15/10 000 pYrs (95% CI 12 to 19) and 7/10 000 pYrs (95% CI 4 to 12) in the nbDMARD cohort. Following adjustment using IPTW, there was no significant difference in the risk of VLE for TNFi compared to nbDMARD-exposed patients (adjHR 1.27; 95% CI 0.40 to 4.04; table 2). Rheumatoid factor-positive status, disease duration, baseline DAS28 and HAQ scores were associated with a higher risk while baseline and concomitant sulfasalazine and concomitant methotrexate were associated with a lower risk (table 3). Exclusion of secondary causes leading to VLE demonstrated no significant differences between groups (adjHR 1.05; 95% CI 0.32 to 3.45; see online supplementary table S3).

TNFi median time to first LLE was 1.2 years for TNFi patients (IQR 0.6–2.5) and 1.0 year (IQR 0.9–1.4) for nbDMARD patients. For VLEs, median time to event was 1 year (IQR 0.5–2.5) compared to 1.8 years (IQR 0.9–3.3) for TNFi and nbDMARD patients, respectively. The hazard for LLE and VLE in the TNFi-treated cohort was greatest in the early months of treatment (figure 2) then steadily decreased over the course of follow-up.

Characteristics of events
For LLE, 48/54 (89%) patients exposed to anti-TNF had cutaneous involvement and was the sole manifestation (plus ANA-positive or consistent skin biopsy) in 30/54 (56%). Of the LLE cases, three patients were known to be ANA-positive at baseline with no SLE manifestations prior to treatment. Five patients (4 TNFi and 1 nbDMARD) were reported to have renal involvement with biopsy results available in three patients (class IV lupus nephritis, immune complex glomerulopathy on
|                               | nbDMARD (n=3673) | All TNFi (n=12 937) | p Value* | First TNFi drug | Etanercept (n=4516) | Adalimumab (n=4362) | Infliximab (n=3363) | Certolizumab (n=696) | p Value† |
|--------------------------------|------------------|---------------------|----------|-----------------|---------------------|---------------------|---------------------|----------------------|----------|
| **Demographic features**       |                  |                     |          |                 |                     |                     |                     |                      |          |
| Age, mean (SD) years           | 60 (12)          | 56 (12)             | <0.001   |                 | 56 (12)             | 57 (12)             | 56 (12)             | 56 (12)              | 0.012    |
| Gender, % female               | 72               | 76                  | <0.001   |                 | 77                  | 76                  | 76                  | 76                   | 0.62     |
| Rheumatoid factor-positive, %  | 2135 (58)        | 8199 (63)           | <0.001   |                 | 2883 (64)           | 2688 (62)           | 2250 (67)           | 378 (58)             | <0.001   |
| **Ethnicity**                  |                  |                     |          |                 |                     |                     |                     |                      |          |
| White                          | 2952 (80)        | 10 467 (81)         | <0.001   |                 | 3638 (81)           | 3588 (83)           | 2795 (83)           | 446 (64)             |          |
| Black                          | 24 (0.6)         | 86 (0.7)            |          |                 | 28 (0.6)            | 34 (0.8)            | 19 (0.6)            | 5 (0.7)              | 0.42     |
| South Asian                    | 32 (0.9)         | 228 (2)             |          |                 | 82 (2)              | 73 (2)              | 65 (2)              | 8 (1)                |          |
| Chinese                        | 2 (0.1)          | 31 (0.2)            |          |                 | 9 (0.2)             | 12 (0.3)            | 9 (0.2)             | 1 (0.2)              |          |
| Other                          | 15 (0.4)         | 117 (0.9)           |          |                 | 36 (0.8)            | 31 (0.7)            | 41 (1.2)            | 9 (1)                |          |
| Not recorded                   | 648 (18)         | 2002 (16)           |          |                 | 723 (16)            | 624 (14)            | 428 (13)            | 227 (32)             |          |
| **Smoking history, n (%)**     |                  |                     |          |                 |                     |                     |                     |                      |          |
| Current smoker                 | 869 (24)         | 2762 (21)           | <0.001   |                 | 911 (20)            | 980 (23)            | 734 (22)            | 137 (20)             | <0.001   |
| Former smoker                  | 1452 (40)        | 4888 (38)           |          |                 | 1728 (38)           | 1660 (38)           | 1274 (38)           | 226 (33)             |          |
| Never smoked                   | 1334 (36)        | 5159 (40)           |          |                 | 1830 (41)           | 1683 (38)           | 1338 (40)           | 308 (44)             |          |
| Not recorded                   | 18 (0.5)         | 128 (1)             |          |                 | 47 (1)              | 39 (1)              | 17 (0.5)            | 25 (3)               |          |
| **Disease duration, median (IQR)** | 6 (1–15)     | 10 (5–18)           | <0.001   |                 | 11 (5–19)           | 10 (5–18)           | 12 (6–19)           | 5 (2–12)             | <0.001   |
| **DAS28 score, mean (SD)**     | 5.1 (1.3)        | 6.5 (1)             | <0.001   |                 | 6.5 (1)             | 6.4 (1)             | 6.6 (1)             | 5.9 (1)              | <0.001   |
| **HAQ score, mean (SD)**       | 1.5 (0.8)        | 2.0 (0.6)           | <0.001   |                 | 2.0 (0.6)           | 1.9 (0.6)           | 2.1 (0.6)           | 1.5 (0.8)            | <0.001   |
| **Comorbidity, n (%)**         |                  |                     |          |                 |                     |                     |                     |                      |          |
| None                           | 1544 (42)        | 6031 (47)           | <0.001   |                 | 2026 (45)           | 2060 (47)           | 1582 (47)           | 363 (52)             | 0.001    |
| 1 comorbidity                  | 1270 (35)        | 4397 (34)           |          |                 | 1522 (34)           | 1476 (34)           | 1177 (35)           | 222 (32)             |          |
| 2 comorbidity                  | 596 (16)         | 1839 (14)           |          |                 | 701 (15)            | 601 (14)            | 457 (14)            | 80 (11)              |          |
| ≥3 comorbidities               | 263 (7)          | 670 (5)             |          |                 | 267 (6)             | 225 (5)             | 147 (4)             | 31 (5)               |          |
| **Treatment-related factors**  |                  |                     |          |                 |                     |                     |                     |                      |          |
| Number of prior nbDMARDS, median (IQR) | 2 (1–3)     | 3 (3–5)             | <0.001   |                 | 4 (3–5)             | 3 (2–4)             | 4 (3–5)             | 3 (2–3)              | <0.001   |
| On methotrexate, n (%)         | 2449 (67)        | 7932 (61)           | <0.001   |                 | 1921 (43)           | 2554 (59)           | 2983 (89)           | 474 (68)             | <0.001   |
| On sulfasalazine, n (%)        | 1245 (34)        | 2395 (18)           | <0.001   |                 | 682 (15)            | 971 (22)            | 513 (15)            | 229 (33)             | <0.001   |
| On leflunomide, n (%)          | 495 (13)         | 1182 (9)            | <0.001   |                 | 377 (8)             | 495 (11)            | 244 (7)             | 66 (9)               | <0.001   |
| On azathioprine, n (%)         | 93 (2)           | 309 (2)             | 0.62     |                 | 123 (3)             | 91 (2)              | 92 (3)              | 3 (0.4)              | 0.001    |
| On minocycline, n (%)          | 1 (0.03)         | 18 (0.1)            | 0.08     |                 | 5 (0.1)             | 7 (0.2)             | 6 (0.2)             | 0                    | 0.63     |
| On hydroxychloroquine, n (%)   | 639 (17)         | 1842 (14)           | <0.001   |                 | 519 (11)            | 716 (16)            | 348 (10)            | 259 (37)             | <0.001   |
| Baseline steroid use, n (%)    | 836 (23)         | 5348 (41)           | <0.001   |                 | 2018 (45)           | 1617 (37)           | 1541 (46)           | 172 (25)             | <0.001   |

*p Value represents the significance of differences between the nbDMARD and TNFi cohorts using χ² tests for categorical outcomes and Wilcoxon rank sum tests for continuous variables.
†p Value represents the significance of differences between the four TNFi drugs using χ² tests for categorical outcomes and Kruskal-Wallis rank tests for continuous variables. Values <1 are represented up to one decimal point.
DAS28, 28 joint count Disease Activity Score; HAQ, Health Assessment Questionnaire; nbDMARDs, non-biological disease-modifying antirheumatic drugs; TNFi, tumour necrosis factor-α inhibitor.
Table 2  Crude incidence rates and HRs for lupus/vasculitis type events in nbDMARD and TNFi-treated patients (on drug+90 days analysis)

|               | nbDMARD (n=3673) | All TNFi (n=12 937) | Etanercept (n=4516) | Adalimumab (n=4362) | Infliximab (n=3363) | Certolizumab (n=696) |
|---------------|------------------|---------------------|---------------------|---------------------|---------------------|----------------------|
| Lupus-like events |      |                     |                     |                     |                     |                      |
| Total follow-up time (patient-years) | 20 815 | 53 159 | 21 595 | 17 343 | 13 181 | 1040 |
| Follow-up per subject, median (IQR) | 6.5 (3.4–9.0) | 5.1 (2.0–8.9) | 6.3 (2.5–10.0) | 5.3 (2.2–8.0) | 4.2 (1.6–8.4) | 1.5 (0.8–2.6) |
| Number | 5 | 54 | 20 | 11 | 23 | 0 |
| Crude incidence rate of lupus-like event per 10 000 person-years (95% CI) | 2.4 (1.0 to 5.7) | 10.2 (7.8 to 13.2) | 9.3 (6.0 to 14.3) | 6.3 (3.5 to 11.5) | 17.5 (11.6 to 26.3) | – |
| Unadjusted HR (95% CI) Referent | 3.93 (1.57 to 9.83)* | 3.83 (1.44 to 10.21)* | 2.40 (0.83 to 6.92) | 6.59 (2.50 to 17.36)* | – | – |
| Age and gender adjusted (95% CI) Referent | 3.72 (1.47 to 9.35)* | 3.60 (1.34 to 9.64)* | 2.26 (0.78 to 6.53) | 6.28 (2.38 to 16.61)* | – | – |
| Propensity score adjusted HR (95% CI)† Referent | 1.86 (0.52 to 6.58) | 1.41 (0.41 to 4.90) | 1.77 (0.33 to 9.36) | 2.65 (0.75 to 9.35) | – | – |
| Vasculitis-like events |      |                     |                     |                     |                     |                      |
| Total follow-up time (patient-years) | 20 635 | 52 428 | 21 320 | 17 172 | 12 903 | 1033 |
| Follow-up per subject, median (IQR) | 6.5 (3.4–9.0) | 5.1 (2.0–8.9) | 6.3 (2.5–10.0) | 5.3 (2.2–8.0) | 4.2 (1.6–8.5) | 1.5 (0.8–2.6) |
| Number of vasculitis-like events, n | 14 | 81 | 37 | 18 | 26 | 0 |
| Crude incidence rate of vasculitis-like events per 10 000 person-years (95% CI) | 6.8 (4.0 to 12.4) | 15.5 (12.4 to 19.2) | 17.4 (12.6 to 24.0) | 10.5 (6.6 to 16.6) | 20.2 (13.7 to 29.6) | – |
| Unadjusted HR (95% CI) Referent | 2.12 (1.20 to 3.74)* | 2.58 (1.39 to 4.77)* | 1.38 (0.69 to 2.78) | 2.70 (1.41 to 5.18)* | – | – |
| Age and gender-adjusted HR (95% CI) Referent | 2.31 (1.30 to 4.09)* | 2.84 (1.52 to 5.28)* | 1.50 (0.74 to 3.03) | 2.93 (1.52 to 5.64)* | – | – |
| Propensity score-adjusted HR (95% CI)† Referent | 1.27 (0.40 to 0.40) | 1.72 (0.53 to 5.57) | 0.71 (0.21 to 2.47) | 1.55 (0.46 to 5.20) | – | – |

*p<0.05.
†Adjusted for age, gender, disease duration, baseline DAS28 score, baseline HAQ score, comorbidities, rheumatoid factor-positive status, year of recruitment, baseline steroid use, baseline nbDMARD use and ethnicity.
‡Adjusted for age, gender, disease duration, baseline DAS28 score, baseline HAQ score, comorbidities, rheumatoid factor-positive status, year of recruitment, baseline steroid and nbDMARD use.

DAS28, 28 joint count Disease Activity Score; HAQ, Health Assessment Questionnaire; nbDMARDs, non-biological disease-modifying antirheumatic drugs; TNFi, tumour necrosis factor-α inhibitor.
infliximab and adalimumab, respectively; membranous glomerulonephritis in biological-naïve patient on methotrexate). Only 16.7% and 20% of events met ACR 1997 SLE classification criteria or SLICC 2012 classification criteria, respectively (table 4). Additional treatment following drug cessation such as steroids (IV or oral) or topical treatment (steroids and tacrolimus) was reported in 27 patients in the TNFi cohort (50%) and 1 patient in the nbDMARD cohort (20%).

Approximately two-thirds of cases in each cohort had VLE limited to the skin (table 4). Most common systemic manifestations included digital ischaemia, neurological involvement and respiratory involvement (table 4). Two patients on TNFi were reported to develop renal manifestations, one with renal vasculitis (no biopsy), the second with renal involvement, along with pneumonitis, new thrombus in aorta on CT angiogram and cANCA-positive status. Associated thromboembolic events were reported in four patients (4.9%). Systemic involvement was reported in 30/81 (37%) VLE patients on TNFi. The patient who developed cANCA/PR3-positive vasculitis died following the development of haemorrhagic alveolitis (with leukocytoclastic vasculitis on lung biopsy), new sinusitis and bilateral episcleritis.
| Covariate                              | HR (95% CI) for covariate | HR (95% CI) for anti-TNF agent |
|----------------------------------------|---------------------------|-------------------------------|
| **Lupus-like events**                  |                           |                               |
| Unadjusted                             |                           |                               |
| Age (per year)                         | 0.98 (0.97 to 1.01)       | 3.79 (1.51 to 9.53)           |
| Gender (male referent)                 | 2.74 (1.25 to 6.00)*      | 3.83 (1.53 to 9.59)           |
| Ethnicity (non-white referent)         | 2.90 (1.24 to 6.75)*      | 3.36 (1.34 to 8.43)           |
| Rheumatoid factor-positive             | 1.08 (0.75 to 1.55)       | 3.91 (1.56 to 9.80)           |
| Smoking (current smoking referent)     | 0.96 (0.49 to 1.67)       | 3.95 (1.57 to 9.88)           |
| Disease duration                       | 1.01 (0.99 to 1.04)       | 3.89 (1.55 to 9.77)           |
| Baseline DAS28                         | 1.58 (1.25 to 1.98)*      | 2.38 (0.90 to 6.29)           |
| Baseline HAQ score                     | 1.69 (1.11 to 2.56)*      | 2.73 (1.07 to 6.97)           |
| **Comorbidities (nil referent)**       |                           |                               |
| 1 comorbidity                          | 1.11 (0.65 to 1.91)       | 3.95 (1.58 to 9.90)           |
| 2 comorbidities                        | 0.77 (0.34 to 1.75)       |                               |
| ≥3 comorbidities                       | 1.17 (0.41 to 3.38)       |                               |
| Methotrexate use†                      | 0.91 (0.54 to 1.51)       | 3.92 (1.57 to 9.83)           |
| Baseline methotrexate use              | 1.03 (0.62 to 1.72)       | 3.95 (1.58 to 9.88)           |
| Sulfasalazine use†                     | 0.30 (0.12 to 0.75)*      | 3.38 (1.34 to 8.51)           |
| Baseline sulfasalazine use             | 0.36 (0.16 to 0.84)*      | 3.53 (1.41 to 8.87)           |
| Leflunomide use†                       | 0.73 (0.29 to 1.82)       | 3.92 (1.57 to 9.83)           |
| Baseline leflunomide use               | 0.83 (0.33 to 2.01)       | 3.93 (1.56 to 9.84)           |
| HCQ use†                               | 1.30 (0.70 to 2.45)       | 4.10 (1.63 to 10.31)          |
| Baseline HCQ use                       | 1.57 (0.86 to 2.89)       | 4.02 (1.61 to 10.08)          |
| Minocycline use†                       | 11.20 (1.55 to 80.81)*    | 3.88 (1.55 to 9.72)           |
| Baseline minocycline use               | 14.31 (1.98 to 103.18)*   | 3.88 (1.55 to 9.72)           |
| On steroid at baseline                 | 0.83 (0.49 to 1.36)       | 4.23 (1.68 to 10.62)          |
| **Vasculitis-like event**              |                           |                               |
| Unadjusted                             |                           | 2.12 (1.20 to 3.74)           |
| Age                                    | 1.01 (0.98 to 1.03)       | 2.27 (1.28 to 4.03)           |
| Gender (male referent)                 | 0.67 (0.46 to 1.0)        | 2.15 (1.22 to 3.80)           |
| Ethnicity (non-white referent)         | 0.51 (0.12 to 2.08)       | 2.17 (1.18 to 4.00)           |
| Rheumatoid factor-positive             | 1.82 (1.18 to 2.78)*      | 2.04 (1.16 to 3.61)           |
| Current smoking                        | 1.30 (0.86 to 1.98)       | 2.14 (1.21 to 3.79)           |
| Disease duration                       | 1.03 (1.01 to 1.04)*      | 2.16 (1.20 to 3.90)           |
| DAS score                              | 1.42 (1.20 to 1.68)*      | 1.44 (0.77 to 2.69)           |
| HAQ score                              | 1.65 (1.19 to 2.28)*      | 1.78 (0.93 to 3.42)           |
| **Comorbidities (nil referent)**       |                           |                               |
| 1 comorbidity                          | 1.46 (0.98 to 2.19)       | 2.11 (1.19 to 3.72)           |
| 2 comorbidities                        | 0.69 (0.35 to 1.38)       |                               |
| ≥3 comorbidities                       | 1.16 (0.48 to 2.61)       |                               |
| Methotrexate use†                      | 0.68 (0.47 to 0.98)*      | 2.07 (1.17 to 3.67)           |
| Baseline methotrexate use              | 0.79 (0.54 to 1.14)       | 2.07 (1.17 to 3.66)           |
| Sulfasalazine use†                     | 0.46 (0.29 to 0.82)*      | 1.84 (1.03 to 3.24)           |
| Baseline sulfasalazine use             | 0.56 (0.33 to 0.97)*      | 1.96 (1.10 to 3.47)           |
| Leflunomide use†                       | 0.75 (0.38 to 1.48)       | 2.10 (1.19 to 3.72)           |
| Baseline leflunomide use               | 0.61 (0.27 to 1.38)       | 2.08 (1.18 to 3.68)           |
| HCQ use†                               | 0.81 (0.46 to 1.41)       | 2.11 (1.19 to 3.74)           |
| Baseline HCQ use                       | 0.91 (0.51 to 1.62)       | 2.11 (1.19 to 3.72)           |
| Combination nbDMARDs (≥2, including methotrexate) | 0.66 (0.43 to 1.00) | 2.05 (1.16 to 3.63) |
| On steroid at baseline                 | 1.20 (0.82 to 1.75)       | 2.07 (1.16 to 3.67)           |

The association between candidate confounders and the outcome (first lupus/vasculitis-like event), irrespective of the treatment group. The final column reports the effect of each baseline covariate on the estimated treatment effect.

* p<0.05.
† Use of nbDMARD versus not use during the study period (assumes the risk returns to baseline as soon as the patient is off the drug).

Anti-TNF, tumour necrosis factor-α inhibitor; DAS28, 28 joint count Disease Activity Score; HAQ, Health Assessment Questionnaire; nbDMARDs, non-biological disease-modifying antirheumatic drugs.
necrosis factor using a flexible parametric spline model. TNFi, tumour necrosis factor-α inhibitor.

while on adalimumab. However, systemic treatment with IV methylprednisolone+/−cyclophosphamide was required in the minority of patients treated with TNFi (n=10, 12.3%).

Outcomes following event

Of the 39 patients with LLE, outcomes included complete resolution (72%), partial resolution (+/−revision of diagnosis from RA to mixed connective tissue disease/SLE with on-going treatment) (15%), 1 death (2%) and unknown (11%). In patients who switched to a different biologic following LLE, there was a trend for some patients to have recurrent events on a second/third TNFi compared to switching to rituximab (see online supplementary figure S2). However, quantitative comparisons could not be made due to low numbers of subsequent events. There were three deaths reported in relation to VLEs.

DISCUSSION

This study is the first prospective observational study to specifically assess the risk of lupus and vasculitis events in patients with RA treated with TNFi. Although unadjusted estimates conferred an increased risk of LLE and VLE individually in TNFi-treated patients, following adjustment this no longer remained significant.

These data must be interpreted carefully with some clinically important points to take from these analyses. First, the absolute risk of LLE and VLE remains very small with an incidence rate of 10 and 15 per 10 000 pyps of follow-up in the TNFi-treated cohort, respectively. Second, the majority of events was limited to cutaneous manifestations in both subsets, with resolution of symptoms (+/−treatment) in most of the LLE episodes. Third, there were inherent limitations common to observational studies. There are clear differences between the nbDMARD and TNFi-treated cohorts, the latter as expected and as per the national guidelines, have more severe disease at baseline, which may in turn be a risk factor for the events examined. Indeed, we found factors that reflect baseline disease severity were associated with higher rates of LLE and VLE. We addressed this issue of confounding by indication, by adjustment using a propensity score. The adjusted analysis of LLE and VLE separately did not demonstrate a significant risk attributable to the TNFi itself. It was not possible to distinguish if these cases would have occurred due to RA or TNFi treatment; however, the association of high-disease activity with VLE/LLE would suggest that uncontrolled disease may be responsible for triggering such events. While propensity scores address confounders present at baseline, they do not take into account time-varying confounders such as steroid use, disease activity and changing nbDMARD use or dose over the course of the study. Statistical techniques, such as marginal structural modelling, have been used to address time-varying confounders in RA previously; however, not used in this case as the required variables to generate weights were not measured at regular time points. Finally, while the comparator cohort of nbDMARD active disease patients is one of the strengths of the study, it is important to note the comparator includes exposure to drugs also associated with drug-induced lupus and vasculitis events. Therefore, while there may be no significant differences in adjusted risk when the two groups are compared, this may be due to comparison with a group of patients already at a higher risk of LLE/VLE. Such exposures may therefore introduce bias towards the null hypothesis. We accounted for this by performing sensitivity analyses, which excluded patients on putative drugs in both cohorts, which did not significantly change in the adjusted estimates.

To date, there have been few studies that were able to robustly assess drug-specific risk of these immune-mediated AEs. Such studies have not been adequately powered to definitively answer this question. In our study, infliximab appeared to carry the highest incidence rates of LLE and VLE, followed by etanercept and adalimumab. The highest risk observed with infliximab in the unadjusted analysis may be due to the fact that patients started on the drug were from a historical cohort and experienced more severe disease at the outset. However, after adjustment for confounders, 95% CIs overlapped. Prior studies have faced a number of limitations, including imprecise reported events from spontaneous pharmacovigilance, lack of an accurate denominator of TNFi-exposed patients and absence of an adequate comparator to assess rare outcomes such as immune-mediated AEs. A French pharmacovigilance study recently attempted to examine drug-specific risk of LLEs from spontaneous reports, across all indications (including inflammatory bowel disease), and used a positive and negative control as comparators (known lupus-inducer isoniazid and paracetamol, respectively). In contrast to our study, infliximab and adalimumab

![Figure 2 Spline model demonstrating time-varying risk of lupus and vasculitis events in the TNFi cohort. Hazard for lupus- and vasculitis-like events over time in TNFi cohort, using a flexible parametric spline model. TNFi, tumour necrosis factor-α inhibitor.](image-url)
were found to be associated with higher rates, with etanercept conferring a comparatively lower risk, although 95% CIs also overlapped with all three drugs. Similar to our study, of the 39 cases, few fulfilled SLE classification criteria. Other descriptive studies reported higher rates with infliximab and etanercept for LLE and VLE.²⁵

LLE and VLE appeared to have a time-varying risk in the TNFi-treated cohort. The observation of greater risk of certain outcomes early in the disease course has been described previously with serious infections, including septic arthritis.²⁴–²⁶ For LLE/VLE, there may be a number of possible hypotheses to explain this risk pattern. First, it may be that TNFi patients have more severe disease at baseline (the latter associated with the outcome), which then improves with therapy therefore reflecting a reduction in risk. Second, it may indicate a depletion of susceptible individual’s effect from the TNFi cohort, whereby patients who remain on the drugs are those who can tolerate them while those who are susceptible to the event select themselves out of the population at risk. Third, it may be that patients who are prone to developing LLE and VLE have a genetic predisposition to SLE/vasculitis, through shared genetic pathways common to RA and SLE for instance,²⁷ and following a TNFi exposure ‘trigger’ develops the event early in the course of treatment, unblinding a condition that may have developed regardless. Fourth, it is possible that such events are associated with immunogenicity of the biologic, leading to secondary inefficacy (loss of response)²⁸–³⁰ and eventual switching to another biologic, which would mean such events occur early in the disease course. Finally, it may reflect a true reduction in risk of these events over time.

**Table 4** Descriptive characteristics of lupus and vasculitis-like events

| Characteristics | n (%) | Characteristics | n (%) |
|-----------------|-------|-----------------|-------|
| **Lupus-like events** |       | **Vasculitis-like events** |       |
| Limited to cutaneous manifestations only | 3 (60) | 9 (64.3) | 51 (63.0) |
| Cutaneous involvement (all) | 4 (80) | 48 (89) |       |
| Malar rash | 2 (50) | 6 (12.5) |       |
| Discoid rash | 1 (25) | 8 (16.7) |       |
| Photosensitive rash | – | 8 (16.7) |       |
| SCLE rash | 1 (25) | 2 (4.1) |       |
| Other† | – | 17 (35.4) |       |
| Missing description‡ | – | 7 (14.6) |       |
| Alopecia | – | 17 (13.0) |       |
| Mouth ulcers | 1 (20) | 5 (9.2) |       |
| Constitutional symptoms | 1 (20) | 6 (11.1) |       |
| Serositis (pericardial/pulmonary involvement) | – | 4 (7.4) |       |
| New arthralgia§ | 2 (40) | 10 (18.5) |       |
| Haematological involvement | – | 5 (9.3) |       |
| Neurological involvement | – | 2 (3.7) |       |
| Renal involvement | 1 (20) | 4 (7.4) |       |
| New ANA-positive | 4 (80) | 30 (55.6) |       |
| Anti-dsDNA-positive | 2 (40) | 12 (22.2) |       |
| Low complement (C3/C4) | – | 5 (9.3) |       |
| Antiphospholipid antibodies-positive | 1 (20) | 9 (16.7) |       |
| ACR SLE criteria met | 2 (40) | 11 (20.0) |       |

*Systemic involvement in VLE cases refers to extra-cutaneous involvement outlined below. In the VLE cases, ANCA status was not checked or reported in the majority of cases, with five patients with known positive status during the event (four patients pANCA-positive/MPO –ve and one patient cANCA-positive, PR3-positive).†Other rashes included maculopapular, bullous, chilblain lupus rashes.‡Patients with missing details regarding their cutaneous involvement were reported as cutaneous lupus only. Other positive serology detected in TNFi-treated patients with LLE included anti-Ro/La antibodies in one patient each.§No cases were classified as LLE solely on the basis of being ANA-positive and new arthralgia. All such cases developed arthralgia and other SLE manifestations concomitantly.

ACR, American College of Rheumatology; ANA, antinuclear antibodies; dsDNA, double-stranded DNA; nbDMARDs, non-biological disease-modifying antirheumatic drugs; ENT, ear, nose and throat; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus; SLICC, Systemic Lupus International Collaborating Clinics; TNFi, tumour necrosis factor-α inhibitor.
The increased risk in the TNFi group of LLE and VLE

CONCLUSIONS
The increased risk in the TNFi group of LLE and VLE was not significant after full adjustment of baseline covariates, suggesting no increased risk following adjustment for confounding by indication. The addition of TNFi to nbDMARD, therefore, does not alter the risk of either event in patients with RA selected for TNFi. The absolute risk of LLE and VLE remains low. The risk of both events was time-varying and highest in the first year of treatment. Clinicians should be aware of these rare but potentially important events in TNFi-treated patients, especially as their presentation may not fulfill usual classification criteria at the outset.

Acknowledgements The authors acknowledge the enthusiastic collaboration of all consultant rheumatologists and their specialist nurses in the UK in providing the data. The authors gratefully acknowledge the support of the National Institute for Health Research, through the Comprehensive Local Research Networks at participating centres. In addition, the authors acknowledge support from the BSR Executive, the members of the BSR Registers and Research Committee and the BSRBR-RA Project Team in London for their active role in enabling the register to undertake its tasks. The authors also acknowledge the seminal role of the BSR Clinical Affairs Committee for establishing national biological guidelines and recommendations for such a register. Finally, the authors acknowledge the Arthritis Research UK Centre for Epidemiology who provided the infrastructure support for the study.

Collaborators The web reference of the BSRBR-RA is as follows: http://research.bmh.manchester.ac.uk/Musculoskeletal/research/CIE/pharmacoepidemiology/bsrbr/healthprofessionals/FinalAuthorshipList/. The BSRBR Control Centre Consortium consists of the following institutions (all in the UK): Antrim Area Hospital, Antrim (Dr Nicola Maiden), Cannock Chase Hospital, Cannock Chase (Dr Tom Price), Christchurch Hospital, Christchurch (Dr Neil Hopkinson), Royal Derby Hospital, Derby (Dr Sheila O’Reilly), Dewsbury and District Hospital, Dewsbury (Dr Lesley Hordon), Freeman Hospital, Newcastle-upon-Tyne (Dr Ian Griffiths), Gartnavel General Hospital, Glasgow (Dr Duncan Porter), Glasgow Royal Infirmary, Glasgow (Professor Hilary Capell), Haywood Hospital, Stoke-on-Trent (Dr Andy Hassell), Hope Hospital, Salford (Dr Romela Benitha), King’s College Hospital, London (Dr Ernest Choy), Kings Mill Centre, Sutton-In Ashfield (Dr David Walsh), Leeds General Infirmary, Leeds (Professor Paul Emery), Macclesfield District General Hospital, Macclesfield (Dr Susan Knight), Manchester Royal Infirmary, Manchester (Professor Ian Bruce), Musgrave Park Hospital, Belfast (Dr Allister Taggart), Northol and Norich University Hospital, Norich (Professor David Scott), Poole General Hospital, Poole (Dr Paul Thompson), Queen Alexandra Hospital, Portsmouth (Dr Fiona McCrae), Royal Glamorgan Hospital, Glamorgan (Dr Rhian Goodfelllow), Russells Hall Hospital, Dudley (Professor George Kitas), Selly Oak Hospital, Selly Oak (Dr Ronald Jubb), St Helens Hospital, St Helens (Dr Ricki Abernethy), Weston General Hospital, Weston-super-Mare (Dr Shane Clarke/Dra Sandra Green), Withington Hospital, Manchester (Dr Paul Sanders), Wittybush General Hospital, Haverfordwest (Dr Amanda Coulson), North Manchester General Hospital (Dr Bev Harrison), Royal Lancaster Infirmary (Dr Manv Batkhi) and The Royal Oldham Hospital (Dr Peter Klimiuk).

Contributors MJ and KLH were responsible for the study concept and design. BSRBR Control Centre Consortium carried out acquisition of data. MJ, ML and LK-F wrote the statistical analysis. MJ, WGD and KLH drafted the manuscript. MJ and KLH had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding MJ is supported by an NIHR clinical lectureship and was a Medical Research Council Clinical Training Fellow supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the Medical Research Council (grant number G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca and the Medical Evaluation Unit. WGD was supported by an MRC Clinician Scientist Fellowship (G092272). This report includes independent research supported by the National Institute for Health Research. The authors thank the Arthritis Research UK for their support (grant number 20380). This work was supported by the British Society for Rheumatology (BSR). The BSR commissioned the BSR Biologics Register in rheumatoid arthritis (BSRBR-RA) as a UK wide national project to investigate the safety of biological agents in routine medical practice. DPS and KLH are principal investigators on the BSRBR-RA. BSR receives restricted income from UK pharmaceutical companies, presently Abbvie, Celltrion, Hospira, Pfizer, Samsung, UC and Roche, and in the past Swedish Orphan Biovitrum and MSD. This income finances a wholly separate contract between the BSR and the University of Manchester. The principal investigators and their team have full academic freedom and are able to work independently of pharmaceutical industry influence.

Disclaimer The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health
Research or the Department of Health. All decisions concerning analyses, interpretation and publication are made autonomously of any industrial contribution. Members of the University of Manchester team, BSR trustees, committee members and staff complete an annual declaration in relation to conflicts of interest. All relevant information regarding serious AEs outlined in the manuscript have been reported to the appropriate company as per the contractual agreements/standard operating procedures.

Competing interests MJ has received honoraria/speaker’s fees from Pfizer, Abbvie and UCB. HC has received honoraria, speaker’s fees or grants from Abbvie, Pfizer, UCB, Roche and Celgene. AB has received honoraria, speaker’s fees or grants from Abbvie, Pfizer, Eli-Lilly and Sanofi-Aventis. INB has received honoraria, speaker’s fees or grants GSK, Roche, Pfizer, UCB and Genzyme/Sanofi. KLH has received grants from Pfizer and speaker’s fees from Abbvie.

Ethics approval North West Multicentre Research Ethics Committee (reference 00/08/53).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932–9.
2. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242–51.
3. Takase K, Horton SC, Ganesh A, et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis 2014;73:1695–9.
4. Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associated with loss of response to anti-tumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010;162:780–5.
5. Hoffmann JHO, Hartmann M, Enk AH, et al. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011;165:1355–6.
6. Ladzinski B, Lee KC. Infliximab-induced urticaria. J Emerg Med 2014;46:691–2.
7. Korswagen LA, Bartelds GM, Krieckaert CLM, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with anti-adalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011;63:877–83.
8. De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545–51.
9. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFα antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73:710–12.
10. Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014;53:213–22.
11. National Institute for Health and Clinical Excellence. Rheumatoid arthritis—adalimumab, etanercept and infliximab (TA130). http://guidancerence.org.uk/TA130 (2007).
12. Kidwell JR, Reesack JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206–9.
13. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37:381–7.
14. Williams EL, Gardola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009;48:716–20.
15. Dubois’ Lupus Erythematosus and Related Syndromes 8th edition—ISBN: 9781437718935 US Elsevier Health Bookshop. http://www.us.elsevierhealth.com/rheumatology/dubois-lupus-erythematosus-and-related-syndromes-expert-consult/9781437718935/ (accessed 4 Apr 2015).
16. Hochberg MC. Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
17. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
18. Aksentijevich I, Lunt M, Low ALS, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015;74:1087–93.
19. Goeß V, Berthelot JM, Joly P, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology 2005;44:823–4.
20. Mor A, Pillinger MH, Wortmann RL, et al. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum 2008;38:249–64.
21. Radic M, Martinovic I, Kallert A, Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med 2012;70:12–17.
22. Farragher TM, Lunt M, Plant D, et al. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res 2010;62:664–75.
23. Mousé G, Sorrenti A, Lapeyre-Mestre M, et al. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/ non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014;53:1864–71.
24. Asling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. J Rheumatol 2007;34:2003–8.
25. Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2011;63:1810–14.
26. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914–20.
27. Remmers EF, Ploeg RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977–86.
28. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-TNF drug level testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Arthritis Rheum 2015;67:2011–19.
29. Jani M, Isaacs JD, Morgan AW, et al., BRAGGSS. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis 2017;76:208–13.
30. Bartelds G, Krieckaert C. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460–8.